相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Biochemistry & Molecular Biology
Immacolata Polvere et al.
Summary: Understanding the antibody response to SARS-CoV-2 is crucial for the development of vaccines and therapeutics, but lack of consistency in monitoring methods poses challenges. A peptide-based ELISA assay has been developed to effectively detect antibody response in COVID-19 convalescent individuals, revealing significant differences among subjects.
Article
Immunology
Annika Nelde et al.
Summary: SARS-CoV-2-specific T cell epitopes were identified in convalescent and unexposed individuals, showing cross-reactivity with common cold coronaviruses. The diversity of SARS-CoV-2 T cell responses may be associated with mild symptoms of COVID-19.
Review
Biochemistry & Molecular Biology
Guido Forni et al.
Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.
CELL DEATH AND DIFFERENTIATION
(2021)
Letter
Medicine, General & Internal
Florian Krammer et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Immunology
Ali Pormohammad et al.
Summary: This study systematically reviewed the clinical features of COVID-19 vaccines in clinical trials, finding that mRNA-based and adenovirus-vectored vaccines exhibited different efficacy and side effect profiles. Both types of vaccines showed high efficacy after the first and second doses, with mRNA-based vaccines having higher reported side effects.
Article
Biochemistry & Molecular Biology
Fatima Amanat et al.
Summary: After receiving the SARS-CoV-2 spike mRNA vaccine, individuals showed robust polyclonal antibody responses, with a majority of vaccine-induced antibodies lacking neutralizing activity. However, vaccine-induced RBD binding antibodies may offer substantial protection against viral variants carrying single E484K RBD mutations.
Article
Multidisciplinary Sciences
Ugur Sahin et al.
Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.
Article
Medicine, General & Internal
Robert W. Frenck et al.
Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Daniel M. Altmann et al.
SCIENCE IMMUNOLOGY
(2020)
Article
Medicine, General & Internal
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
